Clomiphene Citrate

Anti-hormone drugs. The mechanism of ovulation stimulation of this product is not fully understood. Since this product has a weak excitatory and strong antagonistic effect on estrogen, ovulation stimulation may be in the hypothalamus. First, antagonism is dominant. By competitively occupying the hypothalamic estrogen receptors, it interferes with the negative feedback of endogenous estrogen, promotes the secretion of luteinizing hormone and follicle-stimulating hormone, and then stimulates the growth of follicles. After the follicles mature, the release of estrogen increases, and the release of preovulatory gonadotropin is stimulated by positive feedback to reach a peak, thus ovulation. The treatment of male infertility may be related to the increase of FSH and LH and the promotion of sperm production.

The main component of this product is clomiphene citrate. Its chemical name is: N, N-diethyl-2-[4-(1, 2-diphenyl-2-chlorovinyl)phenoxy]ethylamine citrate of cis-trans isomer mixture.

1. Treatment of female infertility due to anovulation, suitable for those with a certain level of estrogen in the body; 2. Treatment of corpus luteum insufficiency; 3. Test ovarian function; 4. Detection of male hypothalamic-pituitary-gonadal axis dysfunction; 5. Treatment of male infertility due to oligospermia.

Oral administration: 50 mg per day for 5 days. Start taking the medicine on the 5th day of the menstrual cycle. If the patient is amenorrhea, the progesterone should be taken on the 5th day of withdrawal bleeding. If the patient ovulates but does not conceive after treatment, the original course of treatment can be repeated until conception, or 3-4 courses can be repeated. If the patient does not ovulate after treatment, the dose can be increased to 100 mg per day for 5 days in the next course of treatment. Some patients can only ovulate when the dose reaches 150 mg per day.

1. The more common adverse reactions are: swelling, stomach pain, pelvic or lower abdominal pain (ovarian enlargement or cyst formation or ovarian fibroma enlargement, more obvious ovarian enlargement, usually occurs a few days after stopping the drug). 2. Less common are: blurred vision, double vision, flashes in front of the eyes, light sensitivity, decreased vision, yellowing of the skin and sclera. 3. Attention should be paid to the following reactions if they persist: hot flashes, breast discomfort, constipation or diarrhea, dizziness or vertigo, headache, increased menstrual flow or irregular bleeding, appetite and weight gain, hair loss, depression, mental tension, hyperactivity, insomnia, fatigue, nausea and vomiting, skin rashes, allergic dermatitis, urticaria, frequent urination, etc., and weight loss may also occur. There are very few reports of breast cancer and testicular cancer abroad.

It is contraindicated for patients with unexplained irregular vaginal bleeding, uterine fibroids, ovarian cysts, liver damage, depression, thrombophlebitis, etc. Animal experiments have teratogenic effects and fetal toxicity, so it is contraindicated for pregnant women.

Not yet clear.

Keep away from light and store in sealed container.